Table V.
Patient characteristics.
| Groups, no. (%) | |||
|---|---|---|---|
| Characteristics | Total (n=407) | I 77 (19.0) | NI 330 (81.0) |
| Age, years | |||
| Range | 37–93 | 37–86 | 40–93 |
| Mean ± SD | 66.4±11.5 | 61.6±12.2 | 67.5±11.1 |
| Gender | |||
| Male | 270 | 52 (19.0) | 218 (81.0) |
| Female | 137 | 25 (18.0) | 112 (82.0) |
| Tumor location | |||
| Hepatocellular Ca | 157 | 36 (23.0) | 121 (77.0) |
| Gallbladder Ca | 46 | 6 (12.0) | 40 (88.0) |
| CholangioCa | 54 | 6 (11.0) | 48 (89.0) |
| Pancreatic Ca | 150 | 29 (19.0) | 121 (81.0) |
| Treatment baseline immunotherapy | |||
| Surgery | 124 | 10 (8.0) | 114 (92.0) |
| Radiotherapy | 33 | 15 (45.0) | 18 (55.0) |
| Chemotherapy | 44 | 21 (48.0) | 23 (52.0) |
| Chinese herbal treatment | 36 | 23 (64.0) | 13 (36.0) |
| DC-CIK | 77 | 77 (100.0) | 0 (0.0) |
I, immunotherapy; NI, non-immunotherapy; SD, standard deviation; Ca, carcinoma; DC, dendritic cell; CIK, cytokine-induced killer.